Yarrow Bioscience
Private
Clinical-stage biotech developing monoclonal antibody therapies for autoimmune thyroid diseases (Graves' disease, thyroid eye disease). Lead candidate YB-101 targets TSHR receptor.
Company Info
Sector:Biotechnology
Headquarters:United States
Founded:2020
Website:www.yarrowbioscience.com/
Funding Round:Series B
Total Funding:$70M
Clinical Development Pipeline
YB-101
Target: TSHRRecent News
No recent news updates available for this company.
Leadership Team
Dr. Rebecca Frey
CEO
Deirdre O'Donnell
Exec Director, RTW Investments